The mathematical model was developed to the lifetime clinical benefit of three evaluate cervical cancer prevention strategies. This analysis was performed to investigate the potential incremental benefit of broader oncogenic protection against other carcinogenic HPV types on HPV types 16 and 18. Cervical cancer vaccine candidate CERVARIX can provide greater protection: The theoretical model is based in part on published clinical data, in the United StatesSmithKline was demonstrated erectile dysfunction treatment .
Next, researchers included GSK cervical cancer vaccine candidate in clinical data the model vaccination strategies vaccination strategies. The model assumes both 70 and 100 % vaccination of women aged 13 and that vaccination conferred lifetime protection. HPV 16 and 18 vaccine efficacy was simulated in the model for HPV 16/18 bivalent vaccine clinical studies in line.
All patients were given an initial aggressive chemotherapy . Induce remission. Who remission of were then given more aggressive treatment , typically a autologous stem, with a couple of welcome intensive chemotherapy.
###resources from the National Cancer Institute and the Coleman Leukemia Research Foundation supporting this research.